Bone Biologics
BBLG
3 hedge funds and large institutions have $35.7K invested in Bone Biologics in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
636% more capital invested
Capital invested by funds: $4.85K → $35.7K (+$30.9K)
1.21% more ownership
Funds ownership: 0.25% → 1.45% (+1.2%)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.83K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$62 |
BBLG Hedge Fund Activity: Q2 2026 in Review
3 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2026, worth a combined $35.7K — up 636% from $4.85K a quarter earlier.
Fund positioning in BBLG was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.2K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.83K.
- 3 institutional investors held Bone Biologics (BBLG) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $35.7K of Bone Biologics stock for Q2 2026, up 636% quarter-over-quarter.
- 1 fund opened new Bone Biologics positions in Q2 2026 and 1 closed out, a net change of 0 holders.
- The largest Bone Biologics buyer in Q2 2026 was Citadel Advisors, an estimated $31.2K added.
- The largest Bone Biologics seller in Q2 2026 was Tower Research Capital (TRC), an estimated $2.83K sold.
Based on aggregated 13F filings for Q2 2026.